Business and Finance

Facility, with expected completion of 2025, will specialize in mRNA-based therapies

Maria Whitman, global head of ZS’s pharmaceutical and biotech practice, talks about the upheaval of the pharma business model and what it means for sales reps; the current skills gap in the marketplace; and how mega-mergers could soon be back on the agenda

Deal expands CDMO’s presence in Europe

Investment will grow manufacturing capabilities at Winchester site

East Syracuse site will serve as a hub for company’s US biologics CDMO business

Deal establishes company’s presence in Mexico

Will be investing up to $100 million to expand presence in Taiwan

Location will feature aseptic fill-finish technology

Deal for PROPENSITY4 grows company’s data analytics knowledge

Per supply chain agreement, CDMO will provide analytical product support

Among efforts, part of center’s focus revolves providing tools for product commercialization

Facility will feature biologic manufacturing, along with late-stage research and clinical development of cancer medicines

Cambridge, MA facility to be home to Alexion corporate HQ

Deal for New Jersey cell therapy site totals $44.5 million

Deal adds biopharma services to its capabilities

Will address biologics drug substance and drug product manufacturing services

Factory will reportedly provide capability of manufacturing 3-4 vaccines simultaneously

Acquisition works toward addressing needs of regenerative medicine industry

Includes a 36,000-square-foot addition to Charlottetown location

Campus will feature a CDMO, over 1,000,000 square feet of floor space

The need for supporting services in copay accumulator and best price areas

Product is powered by company’s Opus platform

Collective project expected to enhance the manufacturing supply chain for ATMPs within the UK

Aims to increase presence in affordability market

Deal features $45 million for commercialization of several Big Pharma products